Skip to main content
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1981 Aug;34(8):927–929. doi: 10.1136/jcp.34.8.927

Resistance to rifampicin and isoniazid in strains of Mycobacterium tuberculosis.

S H Siddiqi, A Aziz, Z Reggiardo, G Middlebrook
PMCID: PMC493987  PMID: 6792243

Abstract

Drug susceptibility studies on strains of Mycobacterium tuberculosis isolated from widely different populations of patients and tested by two different techniques indicated that all 55 strains resistant to rifampicin were also resistant to isoniazid, while many strains resistant to isoniazid were found to be susceptible to rifampicin. This observation, which has as yet unknown laboratory and clinical significance, may be particularly useful in management of patients. Further studies are called for to establish this relation.

Full text

PDF
927

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Canetti G., Fox W., Khomenko A., Mahler H. T., Menon N. K., Mitchison D. A., Rist N., Smelev N. A. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ. 1969;41(1):21–43. [PMC free article] [PubMed] [Google Scholar]
  2. Canetti G., Le Lirzin M., Porven G., Rist N., Grumbach F. Some comparative aspects of rifampicin and isoniazid. Tubercle. 1968 Dec;49(4):367–376. doi: 10.1016/s0041-3879(68)80017-0. [DOI] [PubMed] [Google Scholar]
  3. Dickinson J. M., Mitchison D. A. Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol. Tubercle. 1976 Dec;57(4):251–258. doi: 10.1016/s0041-3879(76)80002-5. [DOI] [PubMed] [Google Scholar]
  4. Hobby G. L., Lenert T. F., Maier-Engallena J. In vitro activity of rifampin against the H37RV strain of Mycobacterium tuberculosis. Am Rev Respir Dis. 1969 Mar;99(3):453–456. doi: 10.1164/arrd.1969.99.3.453. [DOI] [PubMed] [Google Scholar]
  5. Hobby G. L., Lenert T. F. The antimycobacterial activity of rifampin. Am Rev Respir Dis. 1968 Apr;97(4):713–714. doi: 10.1164/arrd.1968.97.4.713. [DOI] [PubMed] [Google Scholar]
  6. Lester W. Rifampin: a semisynthetic derivative of rifamycin--a prototype for the future. Annu Rev Microbiol. 1972;26:85–102. doi: 10.1146/annurev.mi.26.100172.000505. [DOI] [PubMed] [Google Scholar]
  7. Middlebrook G., Reggiardo Z., Tigertt W. D. Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir Dis. 1977 Jun;115(6):1066–1069. doi: 10.1164/arrd.1977.115.6.1066. [DOI] [PubMed] [Google Scholar]
  8. Osato T., Shimizu H. [Virulence of rifampicin-resistant tubercle bacilli for experimental animals (preliminary report)]. Kekkaku. 1972 May;47(5):129–134. [PubMed] [Google Scholar]
  9. Tsukamura M. The pattern of resistance development to rifampicin in Mycobacterium tuberculosis. Tubercle. 1972 Jun;53(2):111–117. doi: 10.1016/0041-3879(72)90027-x. [DOI] [PubMed] [Google Scholar]
  10. Verbist L., Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis. 1968 Dec;98(6):923–932. doi: 10.1164/arrd.1968.98.6.923. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES